Published in J Virol on November 01, 2004
Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science (2010) 5.94
Influenza seasonality: underlying causes and modeling theories. J Virol (2006) 4.22
Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol (2008) 2.63
The biology of influenza viruses. Vaccine (2008) 2.58
Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol (2008) 1.95
Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res (2008) 1.86
Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol (2010) 1.83
Influenza A virus neuraminidase limits viral superinfection. J Virol (2008) 1.79
Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J Immunol (2010) 1.74
Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol (2006) 1.74
A genetically engineered waterfowl influenza virus with a deletion in the stalk of the neuraminidase has increased virulence for chickens. J Virol (2009) 1.59
Viral RNA polymerase complex promotes optimal growth of 1918 virus in the lower respiratory tract of ferrets. Proc Natl Acad Sci U S A (2008) 1.53
The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity and transmissibility in ducks. J Virol (2009) 1.50
A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir Viruses (2009) 1.42
Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest (2005) 1.42
Sialic acids as receptor determinants for coronaviruses. Glycoconj J (2006) 1.39
Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clin Vaccine Immunol (2011) 1.37
Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J Virol (2011) 1.35
Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico. PLoS One (2011) 1.32
H5N1 avian influenza virus induces apoptotic cell death in mammalian airway epithelial cells. J Virol (2008) 1.32
Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication. J Virol (2005) 1.31
Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS One (2009) 1.28
Avian Influenza virus glycoproteins restrict virus replication and spread through human airway epithelium at temperatures of the proximal airways. PLoS Pathog (2009) 1.27
Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic Acid receptors. J Virol (2012) 1.25
Influenza virus reassortment occurs with high frequency in the absence of segment mismatch. PLoS Pathog (2013) 1.24
Comparison of mutation patterns in full-genome A/H3N2 influenza sequences obtained directly from clinical samples and the same samples after a single MDCK passage. PLoS One (2013) 1.23
Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice. Proc Natl Acad Sci U S A (2013) 1.22
Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J (2006) 1.19
Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J (2013) 1.19
In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses (2014) 1.17
Functional significance of the hemadsorption activity of influenza virus neuraminidase and its alteration in pandemic viruses. Arch Virol (2009) 1.15
The RNA binding domain of influenza A virus NS1 protein affects secretion of tumor necrosis factor alpha, interleukin-6, and interferon in primary murine tracheal epithelial cells. J Virol (2007) 1.13
Host immune and apoptotic responses to avian influenza virus H9N2 in human tracheobronchial epithelial cells. Am J Respir Cell Mol Biol (2010) 1.13
Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol (2012) 1.11
Optimizing viral protein yield of influenza virus strain A/Vietnam/1203/2004 by modification of the neuraminidase gene. J Virol (2009) 1.10
Mucin biopolymers as broad-spectrum antiviral agents. Biomacromolecules (2012) 1.08
Glycotherapy: new advances inspire a reemergence of glycans in medicine. Chem Biol (2013) 1.04
Novel vaccines against influenza viruses. Virus Res (2011) 1.04
DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis. J Antimicrob Chemother (2009) 1.04
New vaccines against influenza virus. Clin Exp Vaccine Res (2013) 1.04
Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J Virol (2013) 1.02
Role of host-specific amino acids in the pathogenicity of avian H5N1 influenza viruses in mice. J Gen Virol (2009) 1.02
A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein. J Virol (2013) 0.99
Influenza A virus entry into cells lacking sialylated N-glycans. Proc Natl Acad Sci U S A (2012) 0.98
Influenza virus neuraminidase: structure and function. Acta Naturae (2009) 0.98
The short stalk length of highly pathogenic avian influenza H5N1 virus neuraminidase limits transmission of pandemic H1N1 virus in ferrets. J Virol (2013) 0.96
Adjustment of receptor-binding and neuraminidase substrate specificities in avian-human reassortant influenza viruses. Glycoconj J (2008) 0.96
Role of initiating nucleoside triphosphate concentrations in the regulation of influenza virus replication and transcription. J Virol (2008) 0.95
Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. Neuro Oncol (2013) 0.95
The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine (2012) 0.94
Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation. J Virol (2012) 0.94
Virus-like particles as universal influenza vaccines. Expert Rev Vaccines (2012) 0.93
Restricted infectivity of a human-Lineage H3N2 influenza A virus in pigs is hemagglutinin and neuraminidase gene dependent. J Clin Microbiol (2006) 0.93
Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor. PLoS One (2012) 0.92
Biological and protective properties of immune sera directed to the influenza virus neuraminidase. J Virol (2014) 0.92
The low-pH stability discovered in neuraminidase of 1918 pandemic influenza A virus enhances virus replication. PLoS One (2010) 0.91
Occasional review: influenza in COPD: pathogenesis, prevention, and treatment. Int J Chron Obstruct Pulmon Dis (2007) 0.90
Infection of differentiated porcine airway epithelial cells by influenza virus: differential susceptibility to infection by porcine and avian viruses. PLoS One (2011) 0.90
Identification of traditional medicinal plant extracts with novel anti-influenza activity. PLoS One (2013) 0.90
Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules. Antiviral Res (2008) 0.89
A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PLoS One (2012) 0.88
Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate. PLoS One (2013) 0.88
Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob Agents Chemother (2014) 0.88
Towards multiscale modeling of influenza infection. J Theor Biol (2013) 0.87
A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus. PLoS One (2014) 0.86
A 20-amino-acid deletion in the neuraminidase stalk and a five-amino-acid deletion in the NS1 protein both contribute to the pathogenicity of H5N1 avian influenza viruses in mallard ducks. PLoS One (2014) 0.86
Influenza A virus nucleoprotein selectively decreases neuraminidase gene-segment packaging while enhancing viral fitness and transmissibility. Proc Natl Acad Sci U S A (2014) 0.86
Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus. J Pharm Sci (2010) 0.85
Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Adv Vaccines (2015) 0.85
Differentiated swine airway epithelial cell cultures for the investigation of influenza A virus infection and replication. Influenza Other Respir Viruses (2012) 0.84
Optimal Use of Vaccines for Control of Influenza A Virus in Swine. Vaccines (Basel) (2015) 0.83
Search for additional influenza virus to cell interactions. Glycoconj J (2006) 0.83
How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example. J R Soc Interface (2014) 0.83
Influenza A virus neuraminidase protein enhances cell survival through interaction with carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) protein. J Biol Chem (2012) 0.83
New small-molecule drug design strategies for fighting resistant influenza A. Acta Pharm Sin B (2015) 0.82
Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo. J Mol Biol (2013) 0.82
NA proteins of influenza A viruses H1N1/2009, H5N1, and H9N2 show differential effects on infection initiation, virus release, and cell-cell fusion. PLoS One (2013) 0.82
Novel antiviral activity of neuraminidase inhibitors against an avian influenza a virus. Virol J (2011) 0.82
Targets for the induction of protective immunity against influenza a viruses. Viruses (2010) 0.82
Exploring cell tropism as a possible contributor to influenza infection severity. PLoS One (2010) 0.82
Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium. J Virol (2015) 0.81
The threat of avian influenza a (H5N1): part II: Clues to pathogenicity and pathology. Med Microbiol Immunol (2007) 0.81
Broad-spectrum drugs against viral agents. Int J Mol Sci (2008) 0.81
Amino acid residues at positions 222 and 227 of the hemagglutinin together with the neuraminidase determine binding of H5 avian influenza viruses to sialyl Lewis X. Arch Virol (2015) 0.81
Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses. J Virol (2015) 0.81
The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding. Virol J (2015) 0.80
Biophysical measurement of the balance of influenza a hemagglutinin and neuraminidase activities. J Biol Chem (2015) 0.80
Imaging of influenza virus sialidase activity in living cells. Sci Rep (2014) 0.80
Binding kinetics of sulfatide with influenza A virus hemagglutinin. Glycoconj J (2013) 0.80
Alterations in hemagglutinin receptor-binding specificity accompany the emergence of highly pathogenic avian influenza viruses. J Virol (2015) 0.80
Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients. Open Forum Infect Dis (2014) 0.79
The threat of avian influenza A (H5N1). Part III: Antiviral therapy. Med Microbiol Immunol (2007) 0.79
Oseltamivir (Tamiflu(®)) in the environment, resistance development in influenza A viruses of dabbling ducks and the risk of transmission of an oseltamivir-resistant virus to humans - a review. Infect Ecol Epidemiol (2012) 0.79
Comparative glycomics analysis of influenza Hemagglutinin (H5N1) produced in vaccine relevant cell platforms. J Proteome Res (2013) 0.79
Shift in oligosaccharide specificities of hemagglutinin and neuraminidase of influenza B viruses resistant to neuraminidase inhibitors. Glycoconj J (2010) 0.79
Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge. J Virol (2014) 0.78
Filament-producing mutants of influenza A/Puerto Rico/8/1934 (H1N1) virus have higher neuraminidase activities than the spherical wild-type. PLoS One (2014) 0.78
Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A (2004) 12.39
Are we ready for pandemic influenza? Science (2003) 7.20
Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A (2004) 7.18
Mucociliary differentiation of serially passaged normal human tracheobronchial epithelial cells. Am J Respir Cell Mol Biol (1996) 4.34
The neuraminidase of influenza virus. Proteins (1989) 3.54
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res (2002) 3.07
Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res (2001) 2.91
The function of the neuraminidase in membrane fusion induced by myxoviruses. Virology (1980) 1.97
Anti-influenza drugs and neuraminidase inhibitors. Prog Drug Res (2001) 1.16
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A (2004) 7.18
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol (2003) 5.11
Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol (2002) 5.09
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis (2004) 4.82
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
New low-viscosity overlay medium for viral plaque assays. Virol J (2006) 3.92
Interaction of polymerase subunit PB2 and NP with importin alpha1 is a determinant of host range of influenza A virus. PLoS Pathog (2008) 3.37
Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol (2004) 2.99
Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol (2006) 2.80
Ebola virus: from discovery to vaccine. Nat Rev Immunol (2003) 2.72
Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J Virol (2010) 2.38
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol (2006) 2.14
Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep (2003) 1.85
Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J (2004) 1.73
Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. J Virol (2002) 1.71
Differential use of importin-α isoforms governs cell tropism and host adaptation of influenza virus. Nat Commun (2011) 1.65
VP40, the matrix protein of Marburg virus, is associated with membranes of the late endosomal compartment. J Virol (2002) 1.63
Control of apoptosis in influenza virus-infected cells by up-regulation of Akt and p53 signaling. Apoptosis (2007) 1.61
Phylogeny of the SARS coronavirus. Science (2003) 1.56
Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding. Rev Med Virol (2003) 1.51
Phosphorylation of VP30 impairs ebola virus transcription. J Biol Chem (2002) 1.47
VP24 of Marburg virus influences formation of infectious particles. J Virol (2005) 1.46
Avian-virus-like receptor specificity of the hemagglutinin impedes influenza virus replication in cultures of human airway epithelium. Virology (2007) 1.44
Oligomerization and polymerization of the filovirus matrix protein VP40. Virology (2003) 1.42
The nipah virus fusion protein is cleaved within the endosomal compartment. J Biol Chem (2005) 1.42
Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J Virol (2010) 1.40
Influenza B virus with modified hemagglutinin cleavage site as a novel attenuated live vaccine. J Infect Dis (2011) 1.40
Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis (2007) 1.37
Rapid and reliable universal cloning of influenza A virus genes by target-primed plasmid amplification. Nucleic Acids Res (2008) 1.36
Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription. J Virol (2005) 1.30
Influenza A virus replication induces cell cycle arrest in G0/G1 phase. J Virol (2010) 1.30
Receptor-binding profiles of H7 subtype influenza viruses in different host species. J Virol (2012) 1.29
N-Glycans attached to the stem domain of haemagglutinin efficiently regulate influenza A virus replication. J Gen Virol (2002) 1.29
Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J Biol Chem (2003) 1.24
Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J (2006) 1.19
Ubiquitous activation of the Nipah virus fusion protein does not require a basic amino acid at the cleavage site. J Virol (2004) 1.18
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Functional significance of the hemadsorption activity of influenza virus neuraminidase and its alteration in pandemic viruses. Arch Virol (2009) 1.15
Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J Virol (2006) 1.15
MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine (2009) 1.13
Modification of nonstructural protein 1 of influenza A virus by SUMO1. J Virol (2010) 1.13
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Importance of the cytoplasmic tails of the measles virus glycoproteins for fusogenic activity and the generation of recombinant measles viruses. J Virol (2002) 1.08
Lassa virus glycoprotein signal peptide displays a novel topology with an extended endoplasmic reticulum luminal region. J Biol Chem (2004) 1.06
Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity. J Gen Virol (2007) 1.06
Human influenza A viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells. Virology (2003) 1.05
Measles virus nucleocapsid transport to the plasma membrane requires stable expression and surface accumulation of the viral matrix protein. Cell Microbiol (2007) 1.05
Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses. J Virol (2012) 1.03
Measles virus matrix protein is not cotransported with the viral glycoproteins but requires virus infection for efficient surface targeting. Virus Res (2002) 1.02
Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus. J Gen Virol (2008) 1.01
Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol (2005) 1.01
TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice. J Virol (2014) 0.99
Adaptive mutations in the H5N1 polymerase complex. Virus Res (2013) 0.99
Spread of infection and lymphocyte depletion in mice depends on polymerase of influenza virus. Am J Pathol (2009) 0.99
Activation of influenza viruses by proteases from host cells and bacteria in the human airway epithelium. Pathog Dis (2013) 0.94
Alterations in caspase cleavage motifs of NP and M2 proteins attenuate virulence of a highly pathogenic avian influenza virus. Virology (2009) 0.93
Hantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice. J Virol (2002) 0.92
Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants. PLoS Negl Trop Dis (2009) 0.91
The Marburg virus surface protein GP is phosphorylated at its ectodomain. Virology (2002) 0.89
A systematic review and meta-analysis of the impact of native tissue repair for pelvic organ prolapse on sexual function. Int Urogynecol J (2014) 0.88
SARS vaccine protective in mice. Emerg Infect Dis (2005) 0.86
Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants. Virology (2005) 0.85
Intracellular distribution of NS1 correlates with the infectivity and interferon antagonism of an avian influenza virus (H7N1). J Virol (2010) 0.85
Polarized glycoprotein targeting affects the spread of measles virus in vitro and in vivo. J Gen Virol (2004) 0.84
Polymorphism of filovirus glycoproteins. Adv Virus Res (2005) 0.84
Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections. Vaccine (2012) 0.83
Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir Chem Chemother (2011) 0.82
Activation of influenza A viruses by host proteases from swine airway epithelium. J Virol (2013) 0.81
A new approach to an influenza life vaccine: haemagglutinin cleavage site mutants generated by reverse genetics. Berl Munch Tierarztl Wochenschr (2006) 0.81
Glycoprotein targeting signals influence the distribution of measles virus envelope proteins and virus spread in lymphocytes. J Gen Virol (2008) 0.81
Gangliosides are not essential for influenza virus infection. Glycoconj J (2006) 0.77
Gold-containing indoles as anticancer agents that potentiate the cytotoxic effects of ionizing radiation. J Med Chem (2012) 0.77
Influenza virus budding from the tips of cellular microvilli in differentiated human airway epithelial cells. J Gen Virol (2013) 0.76
The microtubule motor protein KIF13A is involved in intracellular trafficking of the Lassa virus matrix protein Z. Cell Microbiol (2013) 0.75
Erratum: H7N9 avian influenza virus - search and re-search. Emerg Microbes Infect (2013) 0.75
Threat of infection: microbes of high pathogenic potential--strategies for detection, control and eradication. Int J Med Microbiol (2005) 0.75
How polymer additives reduce the pour point of hydrocarbon solvents containing wax crystals. Phys Chem Chem Phys (2015) 0.75